BioWorld

April 12, 2007

Transgene, Roche Enter Potential $293M Alliance On HPV Vaccine

Transgene SA entered its first product-development deal, a collaboration worth up to €218 million (US$293) on its late-stage therapeutic vaccine against human papillomavirus-related diseases. (BioWorld Today) Read More

Cell Genesys Boosting Cash Position Via $60M Stock Sale

Finding Mechanisms Of Breast Cancer Metastasis, In Four Akts

Diagnostics, Patients' Input Changing Face Of Medicine

Genaera Restructures Again, To Focus On Obesity Program

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026